| Identification | Back Directory | [Name]
VX-166 | [CAS]
800408-39-3 | [Synonyms]
VX-166
WQNDPVUOABHOHK-KBPBESRZSA-N
Pentanoic acid, 3-[[(2S)-2-[3-[(methoxycarbonyl)amino]-2-oxo-1(2H)-pyridinyl]-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- | [Molecular Formula]
C22H21F4N3O8 | [MDL Number]
MFCD25976862 | [MOL File]
800408-39-3.mol | [Molecular Weight]
531.41 |
| Hazard Information | Back Directory | [Description]
VX-166 is a broad caspase inhibitor, which can be used as a novel potential treatment for sepsis. VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. | [Uses]
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver[1]. | [References]
[1] John Pollard, et al. Treatment of liver diseases with a caspase inhibitor. Patent WO2010120880A1. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|